There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The big pharma companies Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.

ABC News chief medical correspondent Dr. Tara Narula explains the findings of a new study on GLP-1 drugs commonly used for weight loss.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,

Researchers studied medical records of veterans who have diabetes. Prince Harry settles lawsuit with Murdoch papers after apology How To Invest In The S&P 500 (Step By Step) The Star Player Being Kept Out of Cooperstown by a Trash Can What the 14th Amendment says about birthright citizenship 10 Reliable Luxury Cars That Will Last You A Lifetime China's 'artificial sun' shatters nuclear fusion record by generating steady loop of plasma for 1,